Document is current
Any future updates will be listed below
-
Authors
Van der Schueren, Bart https://orcid.org/0000-0003-4754-784X
Vrijlandt, Patrick
Thomson, Andrew
Janssen, Heidi
Dunder, Kristina
- License Information
-
More Information
Article History
Received: 27 March 2024
First Online: 4 May 2024
Acknowledgements
: All current members of the European Medicines Agency's (EMA) Cardiovascular Working Party (CVSWP)—Kristina Dunder (Medical Products Agency, Uppsala, Sweden), Antonio Gomez-Outes (Division of Pharmacology and Clinical Drug Evaluation, Spanish Agency for Medicines and Medical Devices [AEMPS], Madrid, Spain), Alar Irs (Estonian State Agency of Medicines [Ravimiamet], Tartu, Estonia), Clemens Mittmann (Federal Institute for Drugs and Medical Devices, Bonn, Germany), Gabriella Passacquale (Italian Medicines Agency [AIFA], Rome, Italy), Jean-Michel Race (National Agency for the Safety of Medicine and Health Products, St Denis, France) and Patrick Vrijlandt (Dutch Medicines Evaluation Board, Utrecht, the Netherlands, and Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands)—as well as Hans L. Hillege (Dutch Medicines Evaluation Board, Utrecht, the Netherlands; Department of Cardiology/Epidemiology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands), Peter Mol (Dutch Medicines Evaluation Board; Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen) and Martina Weise (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany) were involved in the development of the new guideline on the clinical investigation of medicinal products in the treatment and prevention of diabetes mellitus.
: More details on the new guideline on the clinical investigation of medicinal products in the treatment and prevention of diabetes guideline can be found at .
: No specific grant from any funding agency in the public, commercial or not-for-profit sectors was obtained for the writing of this paper.
: The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Free to read: This content has been made available to all.
